Navigation Links
Study Probes Use of Filter Device to Stop Deadly Blood Clots
Date:3/18/2013

MONDAY, March 18 (HealthDay News) -- The use of a special filter to prevent potentially deadly blood clots from traveling to patients' lungs varies widely among hospitals, a new study finds.

A vena cava filter is placed in the inferior vena cava, the large vein in the abdomen that returns blood from the lower body to the heart. It is one of the treatments for people with blood clots that develop in the veins of the leg or pelvis (deep vein thrombosis).

These blood clots can break free and travel to the lungs, where they can cause severe complications or death. A vena cava filter, which is designed to trap these clots before they reach the lungs, may be the only treatment option for patients who can't be given blood-thinning drugs.

But one expert notes that the evidence around the effectiveness of these devices has never been clear.

"Vena cava filters were once thought to be lifesaving devices in patients [with clots] who could not tolerate the methods of blood thinners," explained Dr. Alisha Oropallo, director of wound care and hyperbarics at North Shore-LIJ Health System, Lake Success, NY.

However, "more recent data has come to light which leads physicians to question the true efficacy of vena cava filters," she said.

In the new study, researchers looked at the use of vena cava filters at 263 hospitals in California between January 2006 and December 2010. The data showed that vena cava filters were used in nearly 15 percent of more than 130,000 hospitalizations for deep vein thrombosis.

However, the frequency of vena cava filter use at the hospital varied widely, ranging from 0 percent to nearly 39 percent of deep vein thrombosis cases. Patient factors associated with the use of vena cava filters included: bleeding at the time of hospital admission; a major operation after admission for deep vein thrombosis; having advanced cancer; and being extremely ill.

Hospital characteristics associated with the use of vena cava filters included having a small number of beds and being in a rural area, according to the study published online March 18 in the journal JAMA Internal Medicine.

The findings suggest that the use of vena cava filters is largely based on a hospital's culture and practice patterns, according to Dr. Richard White, of the University of California, Davis, and colleagues.

Hospitals may be more or less reluctant to use the filters because the data on their effectiveness remains unclear, the researchers said. "The absence of reliable data indicating a clear benefit [or clear harm] associated with [vena cava filter] use likely contributes to the wide variation in use that we observed," they concluded.

Oropallo agreed. "The need for a proper randomized trial [into vena cava filter use] is necessary," she said. "Until such studies are completed, it will remain difficult for physicians to properly guide their patients to the appropriate treatment for certain circumstances."

More information

The American College of Radiology, Radiological Society of North America has more about vena cava filters.

-- Robert Preidt

SOURCES: Alisha Oropallo, MD, Director, Wound Care & Hyperbarics, North Shore-LIJ Health System, Lake Success, N.Y.; JAMA Internal Medicine, news release, March 18, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Patients Health Care Costs Unaffected by Doctors Sex: Study
2. Study confirms difference in radical prostatectomy outcomes between surgeons
3. Consumers View Foods With Green Labeling as Healthier: Study
4. Study shows rising rate of propofol abuse by health care professionals
5. UK study: Epigenetic changes play a key role in development of chemo resistance in BCa
6. New study points to the aggressive potential of small kidney tumors, advocates treatment
7. New study: Incidence and mortality of PCa after termination of PSA-based screening
8. Study shows community approach effective in fight against diabetes
9. Study: Smoking Increases HPV Risks; polyDNA Recommends Gene-Eden-VIR Against HPV
10. Omega XL Reports New Independent Study: Omega-3s Can Boost Children’s IQ
11. Childhood Depression May Be Tied to Later Heart Risk: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Probes Use of Filter Device to Stop Deadly Blood Clots
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent Care ... MD Now’s 28th facility overall and marks the urgent care center's eighth location in ... North of The Falls shopping mall. The new clinic offers a wide array of ...
(Date:6/23/2017)... ... ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an upcoming episode ... Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for more info. ... 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in science and ...
(Date:6/23/2017)... Chicago, IL (PRWEB) , ... June 23, 2017 ... ... insurance management assistance and financial planning services to communities in the greater Chicago ... Children’s Association to offer assistance to underprivileged youth in Chicago. , Founded in ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, ... area with access to asset protection and financial planning services, is teaming up ... improving the lives of children with cancer and other chronic diseases. , The ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... is pleased to welcome Whipple & Company as its newest Partner Firm. Headquartered ... of balancing their clients’ risk while tailoring optimized benefit packages that strengthen the ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology: